Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance
作者： Mary Philip , Andrea Schietinger
关键词: Multidimensional analysis 、 Biology 、 Resistance (ecology) 、 Genomics 、 Immune system 、 Melanoma 、 Cancer therapy 、 Epigenetics 、 Cancer evolution 、 Bioinformatics
摘要: Cancer resistance to therapy occurs through a selection process generally thought be driven by mutations. In recent study, Hugo et al. use multidimensional analysis of the dynamic genetic, transcriptional, epigenetic, and immune landscape alterations in baseline MAPK inhibitor-resistant melanoma tumors, demonstrating role for ‘non-genomic’ drivers cancer evolution.
unirioja.es
elsevier.com
sci-hub.se 参考文章(10)
Andrew J Gentles, Aaron M Newman, Chih Long Liu, Scott V Bratman, Weiguo Feng, Dongkyoon Kim, Viswam S Nair, Yue Xu, Amanda Khuong, Chuong D Hoang, Maximilian Diehn, Robert B West, Sylvia K Plevritis, Ash A Alizadeh, The prognostic landscape of genes and infiltrating immune cells across human cancers Nature Medicine. ,vol. 21, pp. 938- 945 ,(2015) , 10.1038/NM.3909
Stefani Spranger, Riyue Bao, Thomas F. Gajewski, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity Nature. ,vol. 523, pp. 231- 235 ,(2015) , 10.1038/NATURE14404
Willy Hugo, Hubing Shi, Lu Sun, Marco Piva, Chunying Song, Xiangju Kong, Gatien Moriceau, Aayoung Hong, Kimberly B. Dahlman, Douglas B. Johnson, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo, Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance Cell. ,vol. 162, pp. 1271- 1285 ,(2015) , 10.1016/J.CELL.2015.07.061
Michael Hölzel, Anton Bovier, Thomas Tüting, Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nature Reviews Cancer. ,vol. 13, pp. 365- 376 ,(2013) , 10.1038/NRC3498
M. A. Paley, D. C. Kroy, P. M. Odorizzi, J. B. Johnnidis, D. V. Dolfi, B. E. Barnett, E. K. Bikoff, E. J. Robertson, G. M. Lauer, S. L. Reiner, E. J. Wherry, Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. ,vol. 338, pp. 1220- 1225 ,(2012) , 10.1126/SCIENCE.1229620
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok, Immune Checkpoint Blockade in Cancer Therapy Journal of Clinical Oncology. ,vol. 33, pp. 1974- 1982 ,(2015) , 10.1200/JCO.2014.59.4358
Chih-Hao Chang, Jing Qiu, David O’Sullivan, Michael D. Buck, Takuro Noguchi, Jonathan D. Curtis, Qiongyu Chen, Mariel Gindin, Matthew M. Gubin, Gerritje J.W. van der Windt, Elena Tonc, Robert D. Schreiber, Edward J. Pearce, Erika L. Pearce, Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression Cell. ,vol. 162, pp. 1229- 1241 ,(2015) , 10.1016/J.CELL.2015.08.016
Hidetoshi Sumimoto, Fumie Imabayashi, Tomoko Iwata, Yutaka Kawakami, The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells Journal of Experimental Medicine. ,vol. 203, pp. 1651- 1656 ,(2006) , 10.1084/JEM.20051848
Kristina M. Ilieva, Isabel Correa, Debra H. Josephs, Panagiotis Karagiannis, Isioma U. Egbuniwe, Michiala J. Cafferkey, James F. Spicer, Mark Harries, Frank O. Nestle, Katie E. Lacy, Sophia N. Karagiannis, Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma Molecular Cancer Therapeutics. ,vol. 13, pp. 2769- 2783 ,(2014) , 10.1158/1535-7163.MCT-14-0290
Ping-Chih Ho, Jessica Dauz Bihuniak, Andrew N. Macintyre, Matthew Staron, Xiaojing Liu, Robert Amezquita, Yao-Chen Tsui, Guoliang Cui, Goran Micevic, Jose C. Perales, Steven H. Kleinstein, E. Dale Abel, Karl L. Insogna, Stefan Feske, Jason W. Locasale, Marcus W. Bosenberg, Jeffrey C. Rathmell, Susan M. Kaech, Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell. ,vol. 162, pp. 1217- 1228 ,(2015) , 10.1016/J.CELL.2015.08.012